The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

The firm raised its full-year revenue guidance on expectations of growth in the range of 3 to 5 percent but it maintained its full-year EPS guidance.

The firm's shares rose to $62.17 at the close of Tuesday's trading on news that TPG and Blackstone had offered to take the firm private.

According to the FDA, the tubes are not being produced in conformity with good manufacturing practice and have led to false positive lead test results.

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

Last week, readers were most interested in a story about an MOU between Gene Solutions and NEWCL to establish a lab in Taiwan.

NeoGenomics has launched c-MET CDx for NSCLC, an immunohistochemistry companion diagnostic assay for the detection of c-Met overexpression, which is observed in up to half of all patients with ...

The firm presented data at AACR that showed the test had high accuracy when distinguishing ovarian cancer at early stages.

Sekisui Diagnostics has launched the OSOM RSV Test, a 15-minute immunochromatographic assay that qualitatively detects nucleoprotein antigens from respiratory syncytial virus. The test is CLIA-waived ...

In vitro diagnostic company Genes2Me (G2M) has appointed John Bishop to its advisory board, where he will help guide the firm's strategic direction, product development, and market expansion ...

During a fireside chat at the RBC Healthcare Conference, Bio-Rad's CFO Roop Lakkaraju confirmed the firm's prior guide for 130 basis points of net tariff impact, which Connor McNamera, RBC's moderator ...